Kelso Pharma appoints Gordon Cameron as chairman
Kelso Pharma has appointed senior life sciences executive, Gordon Cameron, as its non-executive chairman.
A senior executive with 25 years’ board-level experience in private equity and plc listed businesses, Mr Cameron has worked in the UK and US, primarily in biotech and pharmaceutical services including both contract research organisations (CRO) and contract development and manufacturing organisations (CDMO).
Originally with Ernst & Young, he had several years in investment banking with Rothschild before becoming CFO and then CEO of FTSE-250 international vaccines company, Acambis plc. Mr Cameron has spent the last 15 years as CFO with Quotient Sciences, a private equity-backed international CDMO and CRO. During his time there, revenues grew 15-fold.
Kelso Pharma aims to bring innovative, value-added, specialty medicines to the European healthcare markets, providing medicines that improve the lives of patients in a cost-effective and ethical manner. Kelso Pharma is growing through a blend of company & product acquisitions, partnerships and organic growth, both in the UK and in Europe.
Dr Tom Stratford, Kelso Pharma CEO, said: “We’re thrilled to welcome Gordon to the Kelso Pharma team as our non-executive chairman. He brings extensive industry experience, as well as a deep understanding of growing businesses under private equity ownership.
“Gordon’s experience, skillset and knowledge demonstrate the calibre of people we’re looking to work with at Kelso Pharma. We aim to provide medicines that improve the lives of patients on a daily basis and we look forward to working with Gordon as we continue to grow the business.”
Mr Cameron added: “I’m very excited to be joining Kelso Pharma at a busy and pivotal time for the business as they look to grow, both organically and by acquisition.
“With the aim of providing value-added medicines to the market in an ethical manner with people at the heart of decision making aligns with my own values and I’m looking forward to playing a part in driving Kelso Pharma’s growth.”